PT - JOURNAL ARTICLE AU - Horna, Pedro AU - Weybright, Matthew J AU - Ferrari, Mathieu AU - Jungherz, Dennis AU - Peng, YaYi AU - Akbar, Zulaikha AU - Ilca, F Tudor AU - Otteson, Gregory E AU - Seheult, Jansen N AU - Ortmann, Janosch AU - Shi, Min AU - Maciocia, Paul M AU - Herling, Marco AU - Pule, Martin A AU - Olteanu, Horatiu TI - Dual T-cell constant β chain (TRBC)1 and TRBC2 staining for the identification of T-cell neoplasms by flow cytometry AID - 10.1101/2023.12.01.23299254 DP - 2023 Jan 01 TA - medRxiv PG - 2023.12.01.23299254 4099 - http://medrxiv.org/content/early/2023/12/01/2023.12.01.23299254.short 4100 - http://medrxiv.org/content/early/2023/12/01/2023.12.01.23299254.full AB - The diagnosis of leukemic T-cell malignancies is often challenging, due to overlapping features with reactive T-cells and limitations of currently available T-cell clonality assays. Recently developed therapeutic antibodies specific for the mutually exclusive T-cell receptor constant β chain (TRBC)1 and TRBC2 isoforms provide a unique opportunity to assess for TRBC-restriction as a surrogate of clonality in the flow cytometric analysis of T-cell neoplasms. To demonstrate the diagnostic utility of this approach, we studied 135 clinical specimens with (50) or without (85) T-cell neoplasia, in addition to 29 blood samples from healthy donors. Dual TRBC1 and TRBC2 expression was studied within a comprehensive T-cell panel, in a fashion similar to the routine evaluation of kappa and lambda immunoglobulin light chains for the detection of clonal B-cells. Polytypic TRBC expression was demonstrated on total, CD4+ and CD8+ T-cells from all healthy donors; and by intracellular staining on benign T-cell precursors. All neoplastic T-cells were TRBC-restricted, except for 5 cases (10%) lacking TRBC expression. T-cell clones of uncertain significance were identified in 15 samples without T-cell malignancy (13%), and accounted for smaller subsets than neoplastic clones (median: 4.7% vs. 73% of lymphocytes, p<0.0001). Single staining for TRBC1 produced spurious TRBC1-dim subsets in 21 clinical specimens (16%), all of which resolved with dual TRBC1/2 staining. Assessment of TRBC restriction by flow cytometry provides a rapid diagnostic method to detect clonal T-cells, and to accurately determine the targetable TRBC isoform expressed by T-cell malignancies.Competing Interest StatementMP and PMM are inventors on a patent describing use of TRBC1/2 for diagnosis and treatment of T cell malignancies. MP and MF are inventors on a patent describing TRBC2 antibodies. Autolus Therapeutics owns patents claiming use of TRBC1/2 for diagnosis. MP, MF and ZA own stock in and are employees of Autolus Therapeutics. FTI is a former Autolus employee. All other authors report no conflicts of interest to disclose.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Mayo Clinic Institutional Review Board.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript